Safety and Efficacy of LCI699 in Cushing's Disease Patients
Status:
Completed
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
This exploratory study is a proof of concept study to determine whether LCI699 can safely
reduce the level of urinary free cortisol in patients with Cushing's disease.
In addition, this study evaluated the long term efficacy and safety of LCI699 including an
additional 12 week of treatment followed by a 12 month long term optional extension.
A second extension provided patients who were clinically benefitting from LCI699 an
opportunity to continue to have access to the drug until LCI699 was commercially available
and reimbursed or through the availability of a local access program.